Amryt Pharma plc

Canaccord Genuity acts as Lead Financial Advisor to Amryt Pharma plc on its New $125 Million Senior Credit Facility, Recapitalizing its Balance Sheet

Canaccord Genuity is pleased to announce that on February 22, 2022, Amryt Pharma plc (“Amryt” or “The Company”), (NASDAQ:AMYT), entered into a $125 million senior credit facility, consisting of an $85 million term loan and a $40 million revolving credit facility. Amryt will use a portion of the proceeds to repay its $94 million secured debt and provide Amryt with important strategic flexibility as it looks to continue to grow its global rare disease presence. The new facilities will generate significant annual savings, bringing the interest costs down from 13.0% to a blended rate of SOFR+5.875% (assuming fully drawn), subject to a 0.9% SOFR floor.

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets, including 3 current orphan disease products: metreleptin (Myalept®/ Myalepta®); oral octreotide (Mycapssa®); and lomitapide (Juxtapid®/ Lojuxta®).